2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Abstract Number: 447

The Influence of Risk Presentation Format on Willingness to Start a Medication
Abstract Number: 448

Cross-Cultural and Construct Validity of the Animated Activity Questionnaire to Assess Activity Limitations in Patients with Hip and Knee Osteoarthritis in Different Languages
Abstract Number: 449

the Animated Activity Questionnaire to Assess Activity Limitations in Patients with Hip and Knee Osteoarthritis: Reliability, Responsiveness, and Interpretation
Abstract Number: 450

Coming Full Circle with the Omeract RA Flare Questionnaire (RA-FQ): Further Evaluation of the Properties, Meaningfulness, and Utility through Rasch Analysis and Feedback from RA Patients
Abstract Number: 451

Cross-Sectional and Longitudinal Construct Validity for the Improved Health Assessment Questionnaire Among Adults with Knee Osteoarthritis
Abstract Number: 452

The Efficacy of Motivational Counselling and SMS-Reminders on Daily Sitting Time in Patients with Rheumatoid Arthritis: A Randomised Controlled Trial
Abstract Number: 453

Adaptation and Validation the Systemic Sclerosis Quality of Life Questionnaire into Spanish Using Rasch Analysis
Abstract Number: 454

WITHDRAWN
Abstract Number: 455

Validity, Reliability and Sensitivity to Change of Four Different Patient-Reported Outcomes (PROs) to Measure the Domains Pain, Fatigue, Experienced Disease Activity and General Well-Being in Patients with Rheumatoid Arthritis
Abstract Number: 456

Patient Engagement in Research: Understanding Patient Interest and Needs
Abstract Number: 457

Novel Mechanism Mediated By the IL-23/Th17 Axis Contributing to Auto-Immune Arthritis
Abstract Number: 458

The TAM Receptors Axl and Mer Play a Protective Role in a Temporal and Spatial Manner in Inflammatory Arthritis
Abstract Number: 459

Resident Non-Classical Monocytes Are Critically Important for Tissue Destruction in Arthritis
Abstract Number: 460

TAS5315, a Novel Bruton’s Tyrosine Kinase Inhibitor, Demonstrates Anti-Inflammatory Effect in Autoimmune Disease Models
Abstract Number: 461

Involvement of CD163-Positive Macrophages in the Pathogenesis of Arthritis Via Modulation of Inflammatory Cytokine and Chemokine Expression in the Synovium of a Murine Model

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].